Affordable Access

Tart Cherry Prevents Bone Loss through Inhibition of RANKL in TNF-Overexpressing Mice

Authors
  • moon, nicholas
  • effiong, linda
  • song, lee
  • gardner, thomas r.
  • soung, y.
Publication Date
Dec 29, 2018
Source
MDPI
Keywords
Language
English
License
Green
External links

Abstract

and IL-6. TC also protected bone structure from inflammation-induced bone loss with a reduced ratio of receptor activator of nuclear factor kappa-B ligand (RANKL)/osteoprotegerin (OPG) to a degree comparable to infliximab. Furthermore, unlike with infliximab, TC exhibited a moderate improvement in TNF-mediated decline in bone stiffness. Thus, TC could be used as a prophylactic regimen against future fragility fractures in the context of highly chronic inflammation.

Report this publication

Statistics

Seen <100 times